With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.932710-63-9,4-(Di-tert-butylphosphino)-N,N-dimethylaniline,as a common compound, the synthetic route is as follows.
932710-63-9, Take a dry 10L three-neck reaction flask, dry nitrogen is fully replaced and under nitrogen flow protection,Add 5.5 L of anhydrous tetrahydrofuran, stir and add 540 g of bis(acetonitrile)palladium dichloride.The obtained ligand di-tert-butyl-4-dimethylaminophenylphosphine was further reacted for 30 minutes, and a yellow solid was precipitated. After the reaction was continued for 9 hours at room temperature,After filtration, the filter cake was dipped in anhydrous tetrahydrofuran, drained and dried in a vacuum oven at 60 C.Obtaining a yellow crystalline powdery target product, namely dichlorodi-tert-butyl-(4-dimethylaminophenyl)phosphine palladium, yielding 1440 g to 1445 g,Elemental analysis showed that the product content exceeded 98.0%, the palladium content exceeded 15.0%, and the palladium calculated yield was 97.7% to 98.1%.
As the paragraph descriping shows that 932710-63-9 is playing an increasingly important role.
Reference£º
Patent; Shanxi Ruike New Materials Co., Ltd.; Zhang Wen; Zhao Lei; Hou Yunji; Cai Wanyu; (11 pag.)CN108659054; (2018); A;,
Phosphine ligand
Chiral phosphine ligands in asymmetric synthesis. Molecular structure and absolute configuration of (1,5-cyclooctadiene)-(2S,3S)-2,3-bis(diphenylphosphino)butanerhodium(I) perchlorate tetrahydrofuran solvate